AOR.L Regulatory News (AOR)

26 Oct 2006 07:01

Aortech International PLC26 October 2006 For Immediate Release 26 October 2006 AorTech International plc ("AorTech" or the "Company") Presentation of AorTech polymer heart valve at TCT symposium AorTech International plc (AIM.AOR), the medical device development,biomaterials intellectual property and licensing company, is pleased to announcethe presentation of its polymer heart valve in a percutaneous application todayat Transcatheter Cardiovascular Therapeutics (TCT) symposium in Washington D.C. TCT is the world's premier gathering where the latest trends, research findings,and techniques in interventional vascular medicine are disseminated topracticing physicians from around the world. The symposium features liveprocedures originating from 31 U.S. and international medical centres featuringworld-renowned operators performing complex interventions. Dr. Carlos Ruiz, MD, PhD of the Lennox Hill Heart and Vascular Institute of NewYork, will present an update on the development progress of the AorTech polymerheart valve. Dr Ruiz's presentation will focus on the performance and durabilitycharacteristics of the valve. Dr Ruiz, said: "The performance of the AorTech polymer, Elast-Eon(TM), is the most spectacularof any polymer I have ever seen in the past and, given its physicalcharacteristics, makes this polymer ideally suited for a percutaneous heartvalve leaflet application." Frank Maguire, AorTech's CEO, commented: "We are both honoured and delighted to have such a prominent internationalclinician as Dr Ruiz presenting the advantages of size and performance providedby the AorTech polymer valve, at such a prestigious clinical meeting. We areextremely excited about the prospects for our heart valve technology." For further information please contact: AorTech International plcFrank Maguire, Chief Executive Tel: + 1 801 201 4336 Hogarth Partnership Limited Tel: +44 20 7357 9477Andrew Jaques / Sarah Richardson Notes to editors: About AorTech International plc Listed on AIM in London, AorTech International plc wholly owns AorTechBiomaterials Pty Ltd based in Melbourne, Australia. AorTech Biomaterials wasformed in July 1997 to commercialise a range of medical grade polyurethanes formedical implants developed by the Commonwealth Scientific and IndustrialResearch Organisation (CSIRO). AorTech's Elast-Eon(TM) technology is the product of a decade of fundamentalresearch into biologically stable materials. ElastEon(TM) materials arepatented, high silicone content, polyurethane copolymers which exhibitunparalleled biological and mechanical performance. AorTech is firmly focused on the development and refinement of this material forthe medical community, with the aim of providing a wide range of highperformance Elast-Eon(TM) materials in a variety of application specificformulations and densities, for use in medical devices. Additional information about the Transcatheter Cardiovascular Therapeutics (TCT)symposium and AorTech can be found at www.tct2006.com and www.aortech.comrespectively. This information is provided by RNS The company news service from the London Stock Exchange